Gilead submits new drug application to FDA for fixed-dose combination of Sofosbuvir/Velpatasvir
The NDA is supported by clinical studies exploring the use of 12 weeks of SOF/VEL for patients with genotype 1-6 HCV infection, including patients with compensated cirrhosis and